Program
[14C]-MRM-3379
A development code. Also written as “Low dose of MRM-3379”, “Middle Dose of MRM-3379” and “High dose of MRM-3379”.
Its studies are mostly in Fragile X Syndrome, led by Mirum Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mirum Pharmaceuticals | 21 open or running | phase 2since Oct 2, 2025 | Oct 2, 2025 | Oct 2027phase 2 · NCT07209462 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 2, 2025First study: phase 2 study in Fragile X SyndromeFirst studyNCT07209462 · 60 planned · United States, Spain
- Jun 26, 2026Phase 1 study in Healthy VolunteersNCT07712718 · 7 enrolled · United States
Ahead
- Oct 2027Primary completion: phase 2 study in Fragile X SyndromeNCT07209462
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07712718Healthy Volunteers · United States | 1 | Completed | Jul 8, 2026 | 7 |
| NCT07209462Fragile X Syndrome · United States, Spain | 2 | Recruiting | Oct 2027 | 60 |
How it is read
Names in the registry
- “[14C]-MRM-3379”, 1 entry
- “Low dose of MRM-3379”, 1 entry
- “Middle Dose of MRM-3379”, 1 entry
- “High dose of MRM-3379”, 1 entry
- “Low dose of MRM-3379 Open-Label”, 1 entry
Codes read as this program: MRM3379.
Conditions, from the studies’ own filings
- Fragile X Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.